Paraneoplastic Itch Management

Brandon Rowe, Gil Yosipovitch

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

Paraneoplastic itch occurs as the result of a systemic reaction to an underlying malignancy. Paraneoplastic itch is most commonly associated with lymphoproliferative malignancies and solid tumors that result in cholestasis. Paraneoplastic itch may occur in the absence of a primary rash or in association with dermatologic conditions such as erythroderma, acanthosis nigricans, dermatomyositis, Grover's disease, and eruptive seborrheic keratosis. Treatment of paraneoplastic itch is centered on targeting the underlying malignancy responsible for the systemic reaction. In cases of malignancy that are refractive to treatment, other therapies have been found to be effective for paraneoplastic itch, including selective serotonin reuptake inhibitors, mirtazapine, gabapentin, thalidomide, opioids, aprepitant, and histone deacetylase inhibitors.

Original languageEnglish (US)
Pages (from-to)149-154
Number of pages6
JournalCurrent Problems in Dermatology (Switzerland)
Volume50
DOIs
StatePublished - Jan 1 2016
Externally publishedYes

ASJC Scopus subject areas

  • Dermatology

Fingerprint

Dive into the research topics of 'Paraneoplastic Itch Management'. Together they form a unique fingerprint.

Cite this